Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
This study is a multicenter, open-label, postmarketing surveillance study. The substudy will
 collect information on BMD in adolescents and young adults with GHD or Turner syndrome who
 are completing GH treatment for statural indications.
Inclusion Criteria:

 -  Bone age of at least 15 years for girls or at least 16 years for boys within 6 months
 of obtaining the DXA scan

 -  Previous enrollment in the NCGS core study, 85-036

 -  Tanner Stage 4 or greater

 -  Either spontaneous or induced puberty

 -  Subjects who plan on terminating GH treatment for statural purposes for one or more of
 the following reasons: epiphyseal fusion, slowing growth rate indicates that near
 adult height has been reached, or satisfied with current height

 Exclusion Criteria:

 -  Current therapy with a non Genentech GH product

 -  Pregnancy (to avoid exposure to low levels of radiation from DXA scanners)

 -  Bilateral hip replacement

 -  Weight >130 kg (286 lb.)